41results about How to "Slow down proliferation" patented technology

The invention belongs to the technical field of tumor molecular biology, and specifically relates to the application of circ_2157 in the preparation of nasopharyngeal carcinoma treatment preparations and the treatment preparations. Because siRNA has a good silencing effect, after ensuring that circ_2157 is interfered, the present invention conducts MTT experiments in the nasopharyngeal carcinoma cell lines HONE1, HNE2 and CNE2 that have silenced circ_2157. Compared with the NC group, the proliferation rate of cells in the siRNA group is obvious Slowing down, i.e. silencing circ_2157, suppressed the proliferation of nasopharyngeal carcinoma cells. That is, inhibiting circ_2157 can treat nasopharyngeal carcinoma, which has far-reaching clinical significance and important prospects for promotion and application.

The invention relates to a compound fresh-preserving agent, which is prepared by the following raw materials in proportion by weight: 5-20 nisin from streptococcus lactis, 10-60 sodium dehydroacetate, 5-50 Glucono- beta-lactone, 5-40 Sodium Erythorbate, 5-50 sodium chloride, and 1-50 sodium tripolyphosphate. The compound fresh-preserving agent of the invention uses the synergistic effect of various raw materials to enable the fresh-preserving effect to be obvious and stabilize sense, chemistry and microorganism indexes of meat and meat products, thus prolonging the shelf life of the meat and the meat products; and the invention has the advantages of wide application product range, convenient processing and use, safety and no toxicity.

The invention belongs to the technical field of tumor molecular biology, and specifically relates to the application of circ_ADARB1 in the preparation of nasopharyngeal carcinoma treatment preparations and the treatment preparations. We found for the first time that circ_ADARB1 may be a potential target for NPC treatment. Since siRNA has a good silencing effect, the present invention uses siRNA designed to interfere with circ_ADARB1 at the splicing site at the head-to-tail junction of circular RNA, and performs scratch healing experiments and matrigel invasion in nasopharyngeal carcinoma cell lines HNE2 and CNE2 In the experiment, compared with the control group, the invasion and migration abilities of cells in the siRNA knockdown circ_ADARB1 group were significantly weakened, that is, silencing circ_ADARB1 inhibited the invasion and metastasis of nasopharyngeal carcinoma cells. It shows that inhibiting circ_ADARB1 can treat nasopharyngeal carcinoma, which has far-reaching clinical significance and important promotion and application prospects.

The invention discloses the application of a substance that reduces the expression of USP1 in the preparation of a medicament for treating childhood T-lineage acute lymphoblastic leukemia. The invention discloses a short hairpin RNA forming a stem-loop structure, which is shRNA-1 or shRNA-2. The deubiquitinating enzyme USP1 has the functions of inhibiting cell apoptosis and promoting cell proliferation in T-line acute lymphoblastic leukemia cells. The present invention proves that inhibiting the expression of USP1 can promote the apoptosis of tumor cell leukemia cells and inhibit the proliferation of leukemia cells. The invention provides a new way for the treatment of T-line acute lymphoblastic leukemia, and the deubiquitinating enzyme USP1 is expected to become a potential target of anti-leukemia treatment, and has a very broad application prospect in the medical field.

The invention provides microRNA used for inducing leukemia cell differentiation and application thereof in the induction of erythroid differentiation of tumor cell lines K562. The microRNA not only has the advantages of cheapness, no toxic or side effect, long duration, high transfection efficiency and the like, but also has the characteristics of stronger action and effectiveness of various indexes for tumor cell differentiation compared with a conventional human leukemia cell erythroid differentiation siRNA inducer.

The invention discloses a production method of a high-salt diluted and low-temperature fragrant soy sauce, which comprises the following steps of: (1) curing raw materials including wheat and defatted soybeans, and then uniformly mixing the wheat and the defatted soybeans; (2) inoculating aspergillus oryzae strains to the obtained raw material mixture so as to obtain a yeast; (3) cultivating the yeast for 44-48 hours at a temperature of 25-30 DEG C so as to obtain a mature yeast; (4) adding 2.0-2.5 weight times of saline water into the mature yeast so as to obtain a raw soy sauce mash; (5) moving the raw soy sauce mash to the inside of an airtight fermentation tank for fermenting: firstly fermenting for 23-27 days at a temperature of 13-17 DEG C, then continuing to ferment at a temperature of 28-32 DEG C, and on the 28-32nd days, adding mixed fermentation strains into the fermentation tank and continuing to ferment; in the process of fermentation, stirring by using a compressed air flow; and fermenting for more than six months so as to obtain a mature soy sauce mash; and (6) squeezing and filtering the mature soy sauce mash so as to obtain the low-temperature fragrant soy sauce. According to the invention, the conversion rate of proteins in raw materials is high, and the contents of ammonia nitrogen, total nitrogen, soybean peptides and soybean oligosaccharides in the prepared soy sauce are high.

The invention relates to a method for rapidly culturing a rice suspension cell line, and belongs to the biotechnical field. The method for rapidly culturing the rice suspension cell line includes the following steps: selection of an explant, sterilization of the explant, callus induction, callus subculture, and suspension cell culture. A suspension cell culture medium and a suspension cell subculture treatment technology are improved. During the subculture treatment of suspension cells, the suspension cultured cells are sequentially screened by sterilized screens with the aperture sizes being about 10 meshes, 20 meshes and 40 meshes after the third-time subculture using a liquid medium to filter out large-granule cell clusters and only reserve cell clusters with uniform size, and the good embryogenic suspension cell line is established through the method in 1.5-2 months. The method has the advantages of low cost, simplicity in operation, shortening of the test cycle, and reduction of the suspension cell line contamination risk, is a new efficient and rapid method, and provides a platform for the relevant study of the rice suspension cell line used as an experimental material.

The invention relates to the technical field of Toxoplasma gondii vaccines, in particular to a live attenuated Toxoplasma gondii vaccine lacking the AP2IV-1 gene and a construction method thereof. The present invention provides a Toxoplasma strain with AP2IV-1 gene deletion, and the amino acid sequence of AP2IV-1 is shown in SEQ ID NO.1. Compared with the worm strain, the virulence of the AP2IV-1 gene-deleted strain is significantly reduced, and it has almost no pathogenicity in mice, and has high safety to the host. The AP2IV-1 gene deletion strain can provide long-term and effective immune protection against acute and chronic reinfection of different types of high-dose Toxoplasma gondii, and has the potential to become a live attenuated vaccine for the prevention of toxoplasmosis in animals.

The invention relates to the fields of biotechnology and medicine, and discloses a small interference ribonucleic acid against multiple myeloma and its application. Wherein the nucleotide sequence of the target polynucleotide is shown in any one of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 in the sequence listing. Excessive SUMOylation is associated with poor prognosis in multiple myeloma. In-depth research on the effect and molecular mechanism of SUMOylated Wnt / β‑catenin on multiple myeloma cell proliferation and apoptosis will help to find the root cause of myeloma progression and further To clarify the prognosis and regulation mechanism of multiple myeloma; and then to develop new therapeutic targets for the key to the recurrence of multiple myeloma. The target DNA provided by the present invention can achieve safer and more effective anti-myeloma treatment, and finally realize the multiple myeloma The cure has very important practical significance.

The invention discloses application of a reagent for inhibiting circ_CLASP2 (Cytoplasmic Linker Associated Protein 2) in preparation of a preparation for treating nasopharyngeal darcinoma and the preparation. A research proves that the circ_CLASP2 is inhibited in nasopharyngeal darcinoma cells, and the proliferation, invasion and metastasis of the nasopharyngeal darcinoma cells can be inhibited. Therefore, a circ_CLASP2 inhibitor is used for treating the nasopharyngeal darcinoma and has profound clinical significance and an important popularization and application prospect.